gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Wert-basierte medicine: Was kommt nach EBM? Ansätze zur Kostenanalyse immunsuppressiver Therapie

Meeting Abstract

Search Medline for

  • corresponding author M. D. Becker - Interdisziplinäres Uveitiszentrum Heidelberg
  • A. Lösch - Interdisziplinäres Uveitiszentrum Heidelberg

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogDO.09.05

The electronic version of this article is the complete one and can be found online at:

Published: September 22, 2004

© 2004 Becker et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Value-based medicine is the practice of medicine emphasizing the value received from an intervention. Value is measured by quantifying objectively the improvement in quality of life (1.) and/or the improvement in length of life as a consequence from an intervention (2.). Evidence-based medicine often only measures the improvement gained in length of life, but generally ignores the importance of quality of life changes. Value-based medicine includes the best features of evidence-based medicine and takes evidence-based data to a higher level by incorporating quality of life issues of patients with a disease and builds the value of an intervention. Value-based medicine also includes the costs associated with an intervention. The resources expended for the value gained is measured with cost-utility analysis in terms of the $/QALY (money spend per quality-adjusted life-year gained) in value-based medicine. A review of the current status and the likely future of value-based medicine is given in this talk.